Vancouver, British Columbia, November 17, 2016
- LED Medical Diagnostics Inc. ("LED" or the "Company") (TSX-V: LMD) is pleased to announce the results of a meta-analysis on the clinical use of autofluorescence to assess its accuracy for oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMD) and investigate its applicability in general dental practice. The study by Luo et al 1
titled "Accuracy of Autofluorescence in Diagnosing Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Comparative Study with Aero-Digestive Lesions" was published in Scientific Reports, an online, open access journal from the publishers of Nature, a leading weekly international scientific journal.
The study was a meta-analysis of previously published data to assess the accuracy of autofluorescence in diagnosing OSCC and OPMD and reported the findings of statistical analyses conducted on 24 previously reported studies detecting OSCC and OPMD in 2761 total lesions. The study reported a pooled sensitivity and specificity of the use of autofluorescence for the detection of OSCC and OPMD of 0.89 and 0.80 respectively and concluded that autofluorescence is a promising, non-invasive tool for the early diagnosis of OSCC and OPMD. The studys authors also remark that using autofluorescence technology as an adjunctive imaging tool may be most reliable in the hands of oral specialists but that the use of promising clinical decision making algorithms could facilitate its adoption in primary care.
"The results of this study will be of great interest to patients and practitioners alike," commented Dr. David Gane, CEO of LED. "The results further validate the use of autofluorescence-based imaging tools, such as the VELscope, in the management of oral tissue abnormalities, including oral cancer. This report adds to the growing body of evidence that corroborates the use of the VELscope as an effective adjunct in screening for the presence of oral cancers and pre cancers. As acknowledged in the study, adjunct diagnostic aids are desperately needed by front-line dental practitioners to facilitate the early detection of OSCC and dysplasia."
Dr. David Morgan, CTO of LEDs wholly-owned subsidiary, LED Dental Inc., remarked, "The authors' conclusion pertaining to the importance of using autofluorescence within a clinical decision-making algorithm for general practitioners is something that we wholeheartedly support and have been advocating for years. It is also important to note that although this study is a very thorough analysis of the peer-reviewed literature relating to early diagnosis, the VELscope Vx is not approved as a stand-alone diagnostic device but rather as an adjunct to enhance the visualization of oral abnormalities."
There are more than 40,000 new cases of oral cancer diagnosed in the United States alone every year and early detection is critical for survival; when oral cancer is detected early, the five-year survival rate rises from less than 50% to more than 80%. VELscope systems are used during more examinations for oral cancer and other oral diseases than any other adjunctive device. For more information, visit www.velscope.com
About LED Medical Diagnostics
Founded in 2003 and headquartered in Vancouver, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiaries LED Dental Inc. and LED Dental Ltd, provide dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio. The Company is currently listed on the TSX-V under the symbol LMD, the OTCQX under the symbol LEDIF, as well as the Frankfurt Stock Exchange under the symbol LME.
About Nature Research
Nature Research is a portfolio of high quality products and services across the life, physical, chemical and applied sciences, including journals, online databases and researcher services, which are dedicated to serving the scientific community. Nature (founded in 1869) is the leading weekly, international scientific journal and sits at the heart of the brand. Nature Research also publishes a range of Nature branded research and reviews subscription journals, alongside leading open access multidisciplinary journal Nature Communications and other open access journals, including mega journal Scientific Reports and a range of partner journals known collectively as the Nature Partner Journals. Online, nature.com
provides over 8 million visitors per month with access to Nature Research publications and services, including news and comment from Nature, and the leading scientific jobs board Naturejobs. Nature Research also offers a range of researcher services, including online and in-person training and expert language and editing services.
Nature Research is part of Springer Nature, a leading global research, educational and professional publisher. Springer Nature is the world's largest academic book publisher, publisher of the world's most influential journals and a pioneer in the field of open research. The company numbers almost 13,000 staff in over 50 countries. Springer Nature was formed in 2015 through the merger of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media. For more information, please visit www.nature.com
and follow @nresearchnews and @SpringerNature.
"Accuracy of Autofluorescence in Diagnosing Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Comparative Study with Aero-Digestive Lesions" has been published online in the Scientific Reports, Nature Publishing Group (Scientific Reports, Article number: 29943, Published online: July 15, 2016, doi:10.1038/srep29943). For access to the complete study, visit http://www.nature.com/articles/srep29943
Phone: 905.326.1888, ext. 10
David Gane, CEO
Phone: 604-434-4614 x227
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.